Important Safety Information for Activase (t-PA)
Acute Ischemic Stroke
Activase therapy in patients with pulmonary embolism is contraindicated in the following situations because of an increased risk of bleeding, which could result in significant disability or death:
- Evidence of intracranial hemorrhage on pretreatment evaluation
- Suspicion of subarachnoid hemorrhage on pretreatment evaluation
- Recent (within 3 months) intracranial or intraspinal surgery, serious head trauma, or previous stroke
- History of intracranial hemorrhage
- Uncontrolled hypertension at time of treatment (e.g., > 185 mm Hg systolic or > 110 mm Hg diastolic)
- Seizure at the onset of stroke
- Active internal bleeding
- Intracranial neoplasm, arteriovenous malformation, or aneurysm
- Known bleeding diathesis including but not limited to:
- – Current use of oral anticoagulants (e.g., warfarin sodium) or an International Normalized Ratio (INR) > 1.7 or a prothrombin time (PT) > 15 seconds
- – Administration of heparin within 48 hours preceding the onset of stroke and have an elevated activated partial thromboplastin time (aPTT) at presentation
- – Platelet count < 100,000/mm3
View the full prescribing information.

